Abstract
Many growth factors, leukotrines, and biological ligands are not circulating free in plasma or serum, except in the case of late or disseminated disease. During early tumor growth and angiogenesis, platelets actively and selectively sequester regulators of angiogenesis and, as such, the platelet protein content can be used as a marker of early tumor growth or angiogenesis. With the recent increase in the clinical use of biologic modifiers in cancer and chronic disease therapy, the search for markers of early disease, therapeutic response, and/or recurrence has suggested that analysis of platelet proteins may be more relevant and accurate. We provide a guideline for the proteomic analysis of platelet proteome, placing specific emphasis on angiogenesis regulators, even though other platelet proteins may serve as markers of disease in the future. The analysis of serum/plasma has been fraught with difficulties because of the extraordinarily large number of proteins and because some of the proteins are contained in extraordinarily large amounts, masking the less abundant proteins. Thus, platelets may provide a much more biologically relevant analyte for biomarker discovery.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- Coag:
-
Coagulation, referring to a test used to measure coagulation time of whole blood
- EGF:
-
Epidermal growth factor
- Fbgn:
-
Fibrinogen
- bFGF:
-
Basic fibroblast growth factor
- PGE:
-
Prostaglandin
- PRP:
-
Platelet rich plasma
- PDGF:
-
Platelet derived growth factor
- PPP:
-
Platelet poor plasma
- SELDI-TOF MS:
-
Surface enhanced laser desorption/ionization – time-of-flight mass spectrometry
- SPA:
-
Sinapinic acid
- TFA:
-
Trifluoroacetic acid
- VEGF:
-
Vascular endothelial growth factor
References
Krueger, K.E. 2006. The potential of serum proteomics for detection of cancer: promise or only hope? Onkologie. 29:498–499.
Huang, L.J., Chen, S.X., Huang, Y., Luo, W.J., Jiang, H.H., Hu, Q.H., Zhang, P.F., and Yi, H. 2006. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer. 54:87–94.
Barker, P.E., Wagner, P.D., Stein, S.E., Bunk, D.M., Srivastava, S., and Omenn, G.S. 2006. Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18–19, 2005. Clin Chem. 52:1669–1674.
Kawada, N. 2006. Cancer serum proteomics in gastroenterology. Gastroenterology. 130:1917–1919.
Wu, G.H., Wang, Y.M., Yen, A.M., Wong, J.M., Lai, H.C., Warwick, J., and Chen, T.H. 2006. Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries. BMC. Cancer. 6:136.
Lim, S.B., Jeong, S.Y., Kim, I.J., Kim, D.Y., Jung, K.H., Chang, H.J., Choi, H.S., Sohn, D.K., Kang, H.C., Shin, Y. et al 2006. Analysis of microsatellite instability in stool DNA of patients with colorectal cancer using denaturing high performance liquid chromatography. World J Gastroenterol. 12:6689–6692.
Half, E.E., and Lynch, P.M. 2006. Mutated DNA in the stool--does it have a role in colorectal cancer screening? Nat. Clin Pract. Gastroenterol. Hepatol. 3:594–595.
Zou, H., Harrington, J.J., Klatt, K.K., and Ahlquist, D.A. 2006. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol. Biomarkers Prev. 15:1115–1119.
Watanabe, T., Kobunai, T., Toda, E., Yamamoto, Y., Kanazawa, T., Kazama, Y., Tanaka, J., Tanaka, T., Konishi, T., Okayama, Y. et al 2006. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 66:9804–9808.
Kreike, B., Halfwerk, H., Kristel, P., Glas, A., Peterse, H., Bartelink, H., and van, d., V 2006. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res. 12:5705–5712.
Chang, Y., and Liu, B. 2006. Difference of gene expression profiles between Barrett’s esophagus and cardia intestinal metaplasia by gene chip. J Huazhong. Univ Sci. Technolog. Med. Sci. 26:311–313.
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., and Seeger, R.C. 2006. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl. Cancer Inst. 98:1193–1203.
Folkman, J. 1971. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285:1182–1186.
Perez-Atayde, A.R., Sallan, S.E., Tedrow, U., Connors, S., Allred, E., and Folkman, J. 1997. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am. J. Pathol. 150:815–821.
Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, A., Herken, R., Roncali, L., and Dammacco, F. 1999. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br. J. Cancer. 79:451–455.
Fuhrmann-Benzakein, E., Ma, M.N., Rubbia-Brandt, L., Mentha, G., Ruefenacht, D., Sappino, A.P., and Pepper, M.S. 2000. Elevated levels of angiogenic cytokines in the plasma of cancer patients. Int. J. Cancer. 85:40–45.
Nguyen, M. 1997. Angiogenic factors as tumor markers. Invest New Drugs. 15:29–37.
Dosquet, C., Coudert, M.C., Lepage, E., Cabane, J., and Richard, F. 1997. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res. 3:2451–2458.
Abendstein, B., Daxenbichler, G., Windbichler, G., Zeimet, A.G., Geurts, A., Sweep, F., and Marth, C. 2000. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Res. 20:569–572.
Wong, A.K., Alfert, M., Castrillon, D.H., Shen, Q., Holash, J., Yancopoulos, G.D., and Chin, L. 2001. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc. Natl. Acad. Sci. USA 98:7481–7486.
Rak, J., Klement, P., and Yu, J. 2006. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression. Vnitr. Lek. 52 Suppl 1:135–138.
Johnson, R.A., and Roodman, G.D. 1989. Hematologic manifestations of malignancy. Dis. Mon. 35:721–768.
Langer, H., May, A.E., Daub, K., Heinzmann, U., Lang, P., Schumm, M., Vestweber, D., Massberg, S., Schonberger, T., Pfisterer, I. et al 2006. Adherent platelets recruit and induce differentiation of murine embryonic endothelial progenitor cells to mature endothelial cells in vitro. Circ. Res. 98:e2–10.
Werther, K., Bulow, S., Hesselfeldt, P., Jespersen, N.F., Svendsen, M.N., and Nielsen, H.J. 2002. VEGF concentrations in tumour arteries and veins from patients with rectal cancer. APMIS. 110:646–650.
Verheul, H.M., and Pinedo, H.M. 1998. Tumor Growth: A Putative Role for Platelets? Oncologist. 3:II.
Verheul, H.M., Hoekman, K., Luykx-de Bakker, S., Eekman, C.A., Folman, C.C., Broxterman, H.J., and Pinedo, H.M. 1997. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3:2187–2190.
Klement, G., Yip, T.-T., Cassiola, F., Kikuchi, L., Cervi, D., Podust, V.N., Italiano, J.E., Jr., Wheatley, E., Abou-Slaybi, A., Bender, E. et al 2009. Platelets actively sequester angiogenesis regulators. Blood. 113:2835–2842.
Italiano, J., Richardson, J.L., Folkman, J., and Klement, G. 2006. Blood Platelets Organize Pro- and Anti-Angiogenic Factors into Separate, Distinct Alpha Granules: Implications for the Regulation of Angiogenesis. ASH Annual Meeting Abstracts. 108:393.
Cervi, D., Yip, T.T., Bhattacharya, N., Podust, V.N., Peterson, J., bou-Slaybi, A., Naumov, G.N., Bender, E., Almog, N., Italiano, J.E.J. et al 2008. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 111:1201–1207.
Cervi, D., Yip, T.T., Bhattacharya, N., Podust, V.N., Peterson, J., bou-Slaybi, A., Naumov, G.N., Bender, E., Almog, N., Italiano, J.E.J. et al 2008. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood. 111:1201–1207.
Anderson, N.L., and Anderson, N.G. 2002. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics. 1:845–867.
Davi, G., and Patrono, C. 2007. Platelet Activation and Atherothrombosis. N Engl J Med. 357:2482–2494.
Michelson A.D. 2002. Platelets. Elsevier Science, Academic Press. San Diego, California, USA.
Hantgan, R.R., Taylor, R.G., and Lewis, J.C. 1985. Platelets interact with fibrin only after activation. Blood. 65:1299–1311.
Addonizio, V.P., Jr., Fisher, C.A., Strauss, J.F., III, Wachtfogel, Y.T., Colman, R.W., and Josephson, M.E. 1986. Effects of verapamil and diltiazem on human platelet function. Am J Physiol Heart Circ Physiol. 250:H366-H371.
2004. The Laboratory Mouse (Handbook of Experimental Animals). Elsevier Academic Press. London.
Vermeulen, R., Lan, Q., Zhang, L., Gunn, L., McCarthy, D., Woodbury, R.L., McGuire, M., Podust, V.N., Li, G., Chatterjee, N. et al 2005. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc. Natl. Acad. Sci. USA. 102:17041–17046.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Downing, S.R., Klement, G.L. (2012). Isolation and Proteomic Analysis of Platelets by SELDI-TOF MS. In: Clarke, C., McCarthy, D. (eds) SELDI-TOF Mass Spectrometry. Methods in Molecular Biology, vol 818. Springer, New York, NY. https://doi.org/10.1007/978-1-61779-418-6_12
Download citation
DOI: https://doi.org/10.1007/978-1-61779-418-6_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-61779-417-9
Online ISBN: 978-1-61779-418-6
eBook Packages: Springer Protocols